Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury


Oktay K., Soenmezer M., Oektem O., Fox K., Emons G., Bang H.

ONCOLOGIST, vol.12, no.9, pp.1055-1066, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 9
  • Publication Date: 2007
  • Doi Number: 10.1634/theoncologist.12-9-1055
  • Journal Name: ONCOLOGIST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1055-1066
  • Keywords: chemotherapy, GnRH analogues, ovarian damage, BONE-MARROW-TRANSPLANTATION, OVARIAN FOLLICULAR DEVELOPMENT, ANTI-MULLERIAN HORMONE, YOUNG-WOMEN, PRIMORDIAL FOLLICLES, GNRH ANALOGS, COMBINATION CHEMOTHERAPY, FERTILITY PRESERVATION, POSTNATAL-DEVELOPMENT, MESSENGER-RNA
  • Ankara University Affiliated: No

Abstract

Every year, an increasing number of women with malignant and nonmalignant diseases is successfully treated with cytotoxic chemotherapy and/or radiotherapy. Many of these patients suffer from infertility and gonadal failure as a result of these treatments. At present, these patients may resort to assisted-reproduction techniques to protect their future childbearing potential before the implementation of cytotoxic therapy. While embryo cryopreservation is an established technology, oocyte and ovarian tissue freezing techniques are still investigational. Nevertheless both of these techniques have resulted in live births. Apart from assisted-reproduction techniques, it has been extensively debated whether administration of gonadotropin-releasing hormone (GnRH) analogues in conjunction with chemotherapy can protect ovarian reserve against cytotoxic insult. In this manuscript, we debate the rationale for the effectiveness of GnRH analogue coadministration in preservation of fertility by reviewing the literature, and provide preliminary data to support our views.